{
  "lastUpdate": "2026-01-14T22:34:30.649204",
  "marketData": [
    {
      "ticker": "LLY",
      "company": "Eli Lilly and Company",
      "price": 1073.29,
      "change": -3.9,
      "changePercent": -0.36,
      "marketCap": "962.2B",
      "sentiment": 0.75,
      "lastUpdate": "2026-01-14T22:34:27.912147"
    },
    {
      "ticker": "NVO",
      "company": "Novo Nordisk A/S",
      "price": 58.91,
      "change": -0.73,
      "changePercent": -1.22,
      "marketCap": "261.8B",
      "sentiment": 0.68,
      "lastUpdate": "2026-01-14T22:34:28.437408"
    },
    {
      "ticker": "VKTX",
      "company": "Viking Therapeutics, Inc.",
      "price": 34.34,
      "change": 3.65,
      "changePercent": 11.89,
      "marketCap": "3.9B",
      "sentiment": 0.9,
      "lastUpdate": "2026-01-14T22:34:28.757473"
    },
    {
      "ticker": "AMGN",
      "company": "Amgen Inc.",
      "price": 328.97,
      "change": 4.67,
      "changePercent": 1.44,
      "marketCap": "177.1B",
      "sentiment": 0.73,
      "lastUpdate": "2026-01-14T22:34:29.124010"
    },
    {
      "ticker": "RHHBY",
      "company": "Roche Holding AG",
      "price": 53.96,
      "change": 0.74,
      "changePercent": 1.39,
      "marketCap": "344.0B",
      "sentiment": 0.7000000000000001,
      "lastUpdate": "2026-01-14T22:34:29.563688"
    },
    {
      "ticker": "PFE",
      "company": "Pfizer Inc.",
      "price": 25.58,
      "change": 0.43,
      "changePercent": 1.71,
      "marketCap": "145.4B",
      "sentiment": 0.65,
      "lastUpdate": "2026-01-14T22:34:30.154102"
    }
  ],
  "intelligenceFeed": [
    {
      "date": "Wed, 14 Jan 2026 14:59:25 -0500",
      "headline": "JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma\u2019s cell therapy view",
      "summary": "<p>Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect a rebound in new stock offerings.&nbsp;</p>",
      "source": "BioPharma Dive - Latest News",
      "link": "https://www.biopharmadive.com/news/jpm26-biotech-ipos-novo-wegovy-gsk-cell-therapy/809600/",
      "priority": "medium"
    },
    {
      "date": "Wed, 14 Jan 2026 11:51:00 -0500",
      "headline": "Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill",
      "summary": "<figure><div><img src=\"https://imgproxy.divecdn.com/sK36taOntL0sw2_zWz8nSJ3873bo7plwtI6utL4RRlQ/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjQ1MzYyOTkyXzEuanBn...",
      "source": "BioPharma Dive - Latest News",
      "link": "https://www.biopharmadive.com/news/lilly-obesity-pill-orforglipron-fda-decision-dtc-sales/809598/",
      "priority": "medium"
    },
    {
      "date": "Mon, 12 Jan 2026 17:18:00 -0500",
      "headline": "JPM26: US biotech\u2019s \u2018Sputnik moment,\u2019 Pfizer\u2019s obesity ambitions and Bristol Myers\u2019 big year",
      "summary": "<p>Four recent deals fueled more angst about China&rsquo;s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to appease jittery investors.&nbsp;</p>",
      "source": "BioPharma Dive - Latest News",
      "link": "https://www.biopharmadive.com/news/jpm26-china-biotech-pfizer-obesity-bristol-sarepta-elevidys-sales/809320/",
      "priority": "medium"
    }
  ],
  "upcomingCatalysts": [
    {
      "date": "2026-03-31",
      "event": "Orforglipron FDA Decision",
      "company": "LLY",
      "description": "Priority review for oral GLP-1",
      "type": "regulatory"
    },
    {
      "date": "2026-06-30",
      "event": "CT-388 Phase 3 Initiation",
      "company": "RHHBY",
      "description": "Roche dual GLP-1/GIP",
      "type": "clinical"
    }
  ],
  "metadata": {
    "version": "1.0",
    "dataQuality": {
      "marketData": true,
      "newsItems": true,
      "catalysts": true
    }
  }
}